**Evidence Table E-7. GFR levels in studies comparing of N-acetylcysteine versus placebo or usual care**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author year** | **Measure** | **SG** | **Interven-tions** | **Arm** | **Base-line N analyzed** | **Mean base-line value (SD)** | **Time point 1** | **Time point 1 N analyzed** | **Mean (SD)** | **Comparison\* statistics at time point 1** | **Time point 2** | **Time point 2 N analyzed** | **Mean (SD)** | **Comparison statistics at time point 2** |
| Erturk, 2014[34](#_ENREF_34) | ml/min/1.73 m^2 |  | IV normal saline | 1 | 103 | 44 (10) | 24 hours | 103 | 47 (13) | p= 0.423 | 48 hours | 103 | 45 (13) | p=0.672 |
| Erturk, 2014[34](#_ENREF_34) | ml/min/1.73 m^2 |  | Oral NAC + IV normal saline | 2 | 102 | 46 (9) |  | 102 | 49 (13) |  |  | 102 | 46 (13) |  |
| Erturk, 2014[34](#_ENREF_34) | ml/min/1.73 m^2 |  | IV NAC + IV normal saline | 3 | 102 | 45 (9) |  | 102 | 46 (13) |  |  | 102 | 46 (13) |  |
| Kama, 2014[54](#_ENREF_54) | GFR, units not specified |  | IV Normal Saline | 1 | 35 | 49.7 (95% CI: 39.2-60.3) | 48-72 hours | 35 | 39 (95% CI: 43.8-64.4) | p=0.49 |  |  |  |  |
| Kama, 2014[54](#_ENREF_54) | GFR, units not specified |  | IV NAC in Normal Saline | 2 | 36 | 44 (95 % CI: 33.5-54.4) |  | 36 | 36 (95% CI: 35.9-57.2) |  |  |  |  |  |
| Kama, 2014[54](#_ENREF_54) | GFR, units not specified |  | IV NaHCO3 in Normal Saline | 3 | 36 | 43.5 (95% CI: 33.5-53.5) |  | 36 | 35 (95% CI: 36.2-61.6) |  |  |  |  |  |
| Sar, 2010[99](#_ENREF_99) | mL/min |   | Saline | 1 | 20 | 97.8 (28.6) | 48 hours | 20 | 99.4 (35.7) | p=0.021 |   |  |  |  |
| Sar, 2010[99](#_ENREF_99) | mL/min |   | Saline + NAC | 2 | 25 | 90.9 (25.1) |  | 25 | 90.8 (25.0) |  |  |  |  |  |
| Staniloae, 2009[123](#_ENREF_123) | Mean change in eGFR |   | no NAC  | 1 |  |   | 45-120 hours | 246 | -3.32 (8.1) | p=0.51 |   |  |  |  |
| Staniloae, 2009[123](#_ENREF_123) | Mean change in eGFR |   | NAC | 2 |  |   |  | 168 | -2.79 (7.8) |  |  |  |  |  |

**Evidence Table E-7. GFR levels in studies comparing of N-acetylcysteine versus placebo or usual care (continued)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author year** | **Measure** | **SG** | **Interven-tions** | **Arm** | **Base-line N analyzed** | **Mean base-line value (SD)** | **Time point 1** | **Time point 1 N analyzed** | **Mean (SD)** | **Comparison\* statistics at time point 1** | **Time point 2** | **Time point 2 N analyzed** | **Mean (SD)** | **Comparison statistics at time point 2** |
| Wang, 2008[114](#_ENREF_114) | eGFR measured at baseline and after procedure |   | Saline | 1 | 23 | 57.97 (26.38) | 24 hours | 23 | 63.00 (29.27) | p=0.71 |   |  |  |  |
| Wang, 2008[114](#_ENREF_114) | eGFR measured at baseline and after procedure |   | Saline + NAC | 2 | 23 | 59.54 (47.13) |  | 23 | 68.10 (57.65) |  |  |  |  |  |

eGFR=estimated glomerular filtration rate; GFR=glomerular filtration rate; N=sample size; NAC=N-acetylcysteine; P=p-value; SD=standard deviation; SG=subgroups